Fundraising Fox

Qualigen Therapeutics

Carlsbad,, US · Founded 2008 · Delaware corporation · 1 known investors

BiotechHealthtech

Founders & leadership

KR
Kevin Richardson IIInterim Chief Executive Officer and Chief Financial Officer
JW
John W. BeckExecutive
IE
Ira E. RitterNamed on SEC filing
WM
William M. MerinoNamed on SEC filing
MD
Michael D. StepNamed on SEC filing
MW
Matthew W. FoehrNamed on SEC filing
PV
Paul V. MaierNamed on SEC filing
AJ
Andrew J. RitterNamed on SEC filing
TA
THOMAS ADAMEKNamed on SEC filing
ND
NOAH DOYLENamed on SEC filing
AR
ANDREW RITTERNamed on SEC filing
IR
IRA RITTERNamed on SEC filing

Investors · 1

Sequoia Capitalreported · 2 sourcesMenlo Park · $4.4M – $214M

Reported raises · per SEC filings

Form D private placements

$19.8M disclosed across 5 rounds · 2012–2025

▶$4.5MraisedAug 2025 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert B. LimDirector
  • Braeden LichtiDirector
  • Kevin Richardson IIDirector
  • Campbell BecherExecutive Officer, Director
  • Cody PriceDirector
Offering amount
$4.5M
Amount sold
$4.5M
Placement agents
Univest Securities LLC
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.1MraisedNov 2024 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Braeden LichtiDirector
  • Graydon BenslerDirector
  • Robert LimDirector
  • Kevin Richardson IIExecutive Officer
  • Campbell BecherDirector
  • Cody PriceDirector
Offering amount
$5.1M
Amount sold
$5.1M
Sales commissions
$408K
Placement agents
Univest Securities LLC
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedNov 2018 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ira E. RitterExecutive Officer, Director
  • John W. BeckExecutive Officer
  • Noah DoyleDirector
  • William M. MerinoDirector
  • Michael D. StepDirector
  • Matthew W. FoehrDirector
  • Paul V. MaierDirector
  • Andrew J. RitterExecutive Officer, Director
Offering amount
$6M
Amount sold
$6M
Minimum investment
$1K
Sales commissions
$367.5K
Placement agents
A.G.P./Alliance Global Partners
First sale
Nov 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.7MraisedDec 2014 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew J. RitterExecutive Officer, Director
  • Michael D. StepExecutive Officer, Director
  • Noah DoyleDirector
  • Thomas AdamekDirector
  • Ira E. RitterExecutive Officer, Director
Offering amount
$5.7M
Amount sold
$3.7M
First sale
Dec 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$526.4KraisedFeb 2012 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • THOMAS ADAMEKDirector
  • NOAH DOYLEDirector
  • ANDREW RITTERExecutive Officer
  • LEE WILLIAMSPromoter
  • IRA RITTERExecutive Officer, Director
  • STEVEN MARKOWITZDirector
Offering amount
$3.5M
Amount sold
$526.4K
Minimum investment
$25K
First sale
Feb 2012
Incorporated
Corporation, Delaware, 2008
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Qualigen Therapeutics, Inc. announced that it has received $41 million in funding from Faraday Future Intelligent Electric Inc., Sequoia Capital, IDgo, Inc., Circle Internet Group, Inc. | MarketScreenermarketscreener.com · Sep 2025Faraday Future Investment: $41M Boost in Qualigen Therapeutics for Web3 Growth | Khaleej Timeskhaleejtimes.com · Sep 2025Qualigen Therapeutics Raises $4.5 Million Through Series A-3 Preferred Stock Placementainvest.com · Jul 2025Qualigen to participate in next funding round for NanoSynex - BioSpacebiospace.com · Jan 2025Qualigen Therapeutics sees major executive reshuffle By Investing.cominvesting.com · Sep 2024

Frequently asked questions

Who are Qualigen Therapeutics's investors?
Qualigen Therapeutics's investors include Sequoia Capital.
How much funding has Qualigen Therapeutics raised?
Qualigen Therapeutics has disclosed $19.8M raised across 5 rounds.
Where is Qualigen Therapeutics headquartered?
Qualigen Therapeutics is headquartered in Carlsbad,, US.